Acute Myeloid Leukemia (AML), FISH, Bone Marrow
AML is generally an elderly disease with an incidence of 25/100,000 persons in octogenarians. Its frequency in childhood is about 0.4/100,000. AML comprises 20% of acute leukemias in children and 80% in adults. The most common symptoms include anemia, thrombocytopenia, fever, hepatomegaly and/or splenomegaly (25%) and less than 5 × 109/L leukocyte count (50%).
AML is often caused by chromosomal abnormalities including translocations and deletions and mutations. The multiple recurrent chromosome abnormalities in AML are observed in approximately 60% of AML cases. The most common chromosome abnormalities associated with AML include t(8;21), t(15;17), inv(16), +8, t(6;9), t(8;16), t(1;22), t(9;22), t(3;5) and abnormalities of the MLL gene at 11q23. The most common translocations and gene amplifications are associated mainly with MLL and include AFF1- t(4;11), MLTT4- t(6;11), MLLT3- t(9;11), MLLT10- t(10;11), CREBBP- t(11;16), ELL- t(11;19p13.1), and MLLT1- t(11;19p13.3). AML can also evolve from chromosome abnormalities associated with MDS including inv(3), -5/5q-, -7/7q-, +8, 13q-, 17p-, 20q-, t(1;3), and t(3;21).
The t(8;21)(q22;q22.3) RUNX1-RUNX1T1 abnormality is found in approximately 10% of all AML cases, and patients who harbor this abnormality are considered to have AML regardless of the percentage of blasts in the bone marrow. The inv(16)(p13.1q22) or t(16;16)(p13.1;q22) CBFβ-MYH11 rearrangements are seen in approximately 5% of all cases of adult AML. The t(15;17)(q24.1;q21.1) PML-RARα aberration is basically synonymous with the diagnosis of acute promyelocytic leukemia (APL, AML-M3). It comprises about 9% of all cases of AML. The inv(3)(q21q26.2) or t(3;3)(q21;q26.2) RPN1-EVI1 has 2% incidence in AML. The t(6;9)(p23;q34) DEK-NUP214 is associated with acute megakaryoblastic leukemia with about 1% occurrence mostly in infants and young children. Trisomy 8, del (5q)/t(5q), −7 or del(7q) abnormalities have a relatively higher frequency with 10-15%, 12%, and 14% incidence, respectively. The t(v;11)(v;q23.3) MLL rearrangement is seen 5-8% of cases of AML.
Fluorescence in situ hybridization (FISH) is a method for identification of chromosomal aberrations by usage of specific DNA probes against particular DNA sequences in the nucleus of interphase cells or metaphase chromosomes.
In a clinical setting, the first step is cytogenetic analysis to identify the chromosomal abnormalities. Conventional chromosome analysis is the gold standard for identification of the common, recurrent chromosome abnormalities in AML; however, some of the subtle rearrangements can be missed (e.g. inv[16] and MLL abnormalities). FISH analysis of nonproliferating (interphase) cells with specific probes could detect the common chromosome abnormalities, residual disease, early relapse, and follow-up of therapy in patients with AML.
- Detection and identification of important chromosomal aberration(s) with prognostic effect in acute myeloid leukemia
- Disease management and response to therapy
- As an adjunct to conventional chromosome studies in acute myeloid leukemia
- Chromosomal abnormalities or a neoplastic clone is detected when the percentage of cells with an abnormal clone exceeds the normal reference range for any given probe
- Positive result represents the detection of a higher number of abnormal signals compared to a normal reference for any given probe
- The absence of a neoplastic or abnormal clone does not rule out the presence of a neoplastic disorder
Negative for chromosomal abnormalities
Bone marrow, Whole blood in.sodium heparinized (Green top) vacutainer tube.
Stability
- Ambient - 24 hours
- Refrigerated - 3-5 days
- Frozen - unacceptable
- Clin Chem Lab Med. 2009;47(11):1333-41. [PMID: 19817644]
- Ann Hematol. 2007 May;86(5):311-27. [PMID: 17375301]
- LeukemiaNet. 2010;115(3):453-7. [PMID: 19880497]
- Am J Clin Pathol. 2015 Jun;143(6):873-8. [PMID: 25972330]
- J Assoc Genet Technol. 2014;40(1):11-5. [PMID: 26029947]
- Williams Hematology, 9th ed., McGraw-Hill Education. 2016:173-91.